Brokerages Expect Penumbra Inc (PEN) Will Announce Earnings of $0.17 Per Share
Equities analysts expect Penumbra Inc (NYSE:PEN) to announce earnings per share (EPS) of $0.17 for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Penumbra’s earnings, with the highest EPS estimate coming in at $0.22 and the lowest estimate coming in at $0.12. Penumbra posted earnings per share of $0.06 in the same quarter last year, which suggests a positive year over year growth rate of 183.3%. The firm is expected to issue its next earnings report after the market closes on Tuesday, May 7th.
According to Zacks, analysts expect that Penumbra will report full-year earnings of $0.83 per share for the current fiscal year, with EPS estimates ranging from $0.73 to $0.95. For the next year, analysts expect that the business will report earnings of $1.33 per share, with EPS estimates ranging from $1.26 to $1.41. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Penumbra.
Penumbra (NYSE:PEN) last released its earnings results on Tuesday, February 26th. The company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The firm had revenue of $120.80 million during the quarter, compared to the consensus estimate of $114.93 million. Penumbra had a return on equity of 4.42% and a net margin of 1.48%. The firm’s revenue for the quarter was up 25.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.25 earnings per share.
In other news, Director Bridget O’rourke sold 175 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $145.72, for a total transaction of $25,501.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Adam Elsesser sold 8,000 shares of the stock in a transaction on Thursday, April 11th. The shares were sold at an average price of $141.58, for a total value of $1,132,640.00. The disclosure for this sale can be found here. Insiders have sold a total of 82,261 shares of company stock valued at $12,645,766 in the last quarter. Insiders own 10.70% of the company’s stock.
Large investors have recently made changes to their positions in the company. Amalgamated Bank lifted its position in shares of Penumbra by 63.0% during the 4th quarter. Amalgamated Bank now owns 6,858 shares of the company’s stock valued at $838,000 after acquiring an additional 2,650 shares during the last quarter. Wells Fargo & Company MN lifted its position in shares of Penumbra by 16.3% during the 3rd quarter. Wells Fargo & Company MN now owns 34,160 shares of the company’s stock valued at $5,115,000 after acquiring an additional 4,794 shares during the last quarter. Baillie Gifford & Co. lifted its position in shares of Penumbra by 35.8% during the 4th quarter. Baillie Gifford & Co. now owns 906,022 shares of the company’s stock valued at $110,715,000 after acquiring an additional 239,008 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Penumbra by 2.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,646,066 shares of the company’s stock valued at $396,116,000 after acquiring an additional 68,479 shares during the last quarter. Finally, First Trust Advisors LP lifted its position in shares of Penumbra by 6.7% during the 4th quarter. First Trust Advisors LP now owns 279,456 shares of the company’s stock valued at $34,150,000 after acquiring an additional 17,624 shares during the last quarter. Institutional investors own 81.60% of the company’s stock.
PEN opened at $129.91 on Friday. The company has a market capitalization of $4.49 billion, a price-to-earnings ratio of 254.73, a PEG ratio of 7.42 and a beta of 0.80. Penumbra has a 1-year low of $110.84 and a 1-year high of $167.35.
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Featured Article: Outstanding Shares, Buying and Selling Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.